• A Genetic Link to Atrial Substrate in Hypertrophic Cardiomyopathy?
• A pedigree with hypertrophic cardiomyopathy caused by a thyroxine translocator c.128G>A mutation
• A personalized mRNA signature for predicting hypertrophic cardiomyopathy applying machine learning methods
• A Rare Coincidence of Three Inherited Diseases in a Family with Cardiomyopathy and Multiple Extracardiac Abnormalities
• Advances in risk assessment models for sudden cardiac death in hypertrophic cardiomyopathy
• Aficamten for Obstructive Hypertrophic Cardiomyopathy
• Aficamten for Obstructive Hypertrophic Cardiomyopathy. Reply
• Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy
• An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy
• Analysis of risk factors for complications in echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation
• Atrial and Ventricular Arrhythmia in Adults With Shone Complex: A Single-Center Cohort Study
• Atrial Fibrillation Substrate and Catheter Ablation Outcomes in MYBPC3- and MYH7-Mediated Hypertrophic Cardiomyopathy
• Bibliometrics Analysis of Studies on Hypertrophic Cardiomyopathy From 2018 to 2022
• Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with hypertrophic cardiomyopathy
• Cardiac disease discrimination from 3D-convolutional kinematic patterns on cine-MRI sequences
• Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathy
• Characteristics and outcomes associated with sarcomere mutations in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis
• Clinical exome sequencing unravels the diverse spectrum of genetic heterogeneity and genotype-phenotype correlations in hypertrophic cardiomyopathy
• Clinical signs associated with severe ST segment elevation in three cats with a hypertrophic cardiomyopathy phenotype
• Comparison of Drug Therapy Efficacy in Patients With Hypertrophic Cardiomyopathy: A Network Meta-Analysis
• Comparison of four electrocardiographic criteria for the detection of cardiac abnormalities in Singapore athletes
• Complete mitochondrial genomes of patients from Thailand with cardiovascular diseases
• Correlation between coronary artery tortuosity and poor prognosis in patients with septal hypertrophic cardiomyopathy
• Defining the variant-phenotype correlation in patients affected by Noonan syndrome with the RAF1:c.770C>T p.(Ser257Leu) variant
• Deriving phenotype-representative left ventricular flow patterns by reduced-order modeling and classification
• Detect and define ventricular arrhythmia substrates in hypertrophic cardiomyopathy
• Different clinical presentation, cardiac morphology and gene mutations in two sisters with hypertrophic cardiomyopathy-A case report
• Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing
• Do ACE inhibitors prolong the life of cats with asymptomatic hypertrophic cardiomyopathy?
• Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
• Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers
• Editorial echocardiography for "Incremental Value of Myocardial Global Longitudinal Strain in Predicting Major Adverse Cardiac Events Among Patients with Hypertrophic Cardiomyopathy" By Zhuang H. and colleagues
• Effects of sex on clinical outcomes of hypertrophic cardiomyopathy in Singapore
• Eighteen-Month Real-World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population
• Evaluation of mavacamten in patients with hypertrophic cardiomyopathy
• Evaluation of new predictive scores for sudden cardiac death in childhood hypertrophic cardiomyopathy in a French cohort
• Evaluation of the prognostic value of papillary muscle-free strain in patients with hypertrophic cardiomyopathy
• Exercise Testing to Unmask Latent LVOT Obstruction in a Highly Symptomatic Patient With Hypertrophic Cardiomyopathy
• Exploring Health-Related Quality of Life in Children With Hypertrophic Cardiomyopathy and Relationship to Physical Activity
• Finding an Unobstructed View Toward the Treatment of Nonobstructive Hypertrophic Cardiomyopathy: Lifting the Hunger Fog
• Forskolin is an effective therapeutic small molecule for the treatment of hypertrophic cardiomyopathy through ADCY6/cAMP/PKA pathway
• Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation
• Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review
• Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice
• Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
• Identification of differentially expressed genes to predict the risk of heart failure in older patients with hypertrophic cardiomyopathy
• Impaired longitudinal systolic-diastolic coupling and cardiac response to exercise in patients with hypertrophic cardiomyopathy
• Importance of preload in understanding impaired longitudinal systolic-diastolic coupling in patients with hypertrophic cardiomyopathy
• Incremental value of myocardial global longitudinal strain in predicting major adverse cardiac events among patients with hypertrophic cardiomyopathy
• Integrating Clinical Phenotype With Multiomics Analyses of Human Cardiac Tissue Unveils Divergent Metabolic Remodeling in Genotype-Positive and Genotype-Negative Patients With Hypertrophic Cardiomyopathy
• Integrating machine learning approach to identify sleep-disordered breathing in hypertrophic cardiomyopathy
• Investigation of coagulation and proteomics profiles in symptomatic feline hypertrophic cardiomyopathy and healthy control cats
• It has been 30 years since the first alcohol septal ablation for hypertrophic obstructive cardiomyopathy was performed
• Left ventricular outflow tract obstruction/hypertrophic cardiomyopathy/takotsubo syndrome: A new hypothesis of takotsubo syndrome pathophysiology
• Machine learning and experimental validation of novel biomarkers for hypertrophic cardiomyopathy and cancers
• Machine Learning in Hypertrophic Cardiomyopathy: Nonlinear Model From Clinical and CMR Features Predicting Cardiovascular Events
• Making a case for mitochondria in hypertrophic cardiomyopathy
• Metabolic remodeling and calcium handling abnormality in induced pluripotent stem cell-derived cardiomyocytes in dilated phase of hypertrophic cardiomyopathy with MYBPC3 frameshift mutation
• Microcirculatory dysfunction in hypertrophic cardiomyopathy with chest pain assessed by angiography-derived microcirculatory resistance
• Microstripe pattern substrate consisting of alternating planar and nanoprotrusive regions improved hiPSC-derived cardiomyocytes' unidirectional alignment and functional properties
• Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single-Center, Observational Study
• Modern Perspectives on Hypertrophic Cardiomyopathy-No One Size Fits All
• Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome
• MYH7 R453C induced cardiac remodelling via activating TGF-β/Smad2/3, ERK1/2 and Nox4/ROS/NF-κB signalling pathways
• Myocardial injury mimicking acute myocardial infarction due to coronavirus infection in adults with pre-existing apical hypertrophic cardiomyopathy
• New Perspectives on Early Stage Hypertrophic Cardiomyopathy: Measuring What Matters
• Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy
• Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy
• Ongoing assertion of two-dimensional measurements on differentiation type of left ventricular hypertrophy: Focus on inferior vena cava
• Outcomes after septal myectomy in a cohort of patients with hypertrophic cardiomyopathy
• Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy
• Phenotypic Spectrum of Subclinical Sarcomere-Related Hypertrophic Cardiomyopathy and Transition to Overt Disease
• Pregnancy related complications in women with hypertrophic cardiomyopathy: a nationwide population-based cohort study
• Prevalence of Phenotypic Hypertrophic Cardiomyopathy Among Student Sports Participants
• PRKAG2 syndrome, a rare hypertrophic cardiomyopathy: a Brazilian long-term follow-up with extracardiac disorders
• Programmed ventricular stimulation for risk stratification in hypertrophic cardiomyopathy patients
• Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond
• Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
• Rapidly Progressive Apical Hypertrophic Cardiomyopathy: Not Everything is What It Seems
• Research progress on the treatment of pediatric hypertrophic cardiomyopathy
• Retrograde coronary venous ethanol ablation for ventricular tachycardia in a patient with inaccessible substrate due to previous surgery
• Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy
• Risk Factors of Cardiac Complications in Pregnant Women with Hypertrophic Cardiomyopathy
• Risk profiles for ventricular arrhythmias in hypertrophic cardiomyopathy through clustering analysis including left ventricular strain
• RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy
• Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)
• Temporal trends, prevalence, predictors, and outcomes of heart failure in patients with hypertrophic cardiomyopathy in the United States: Insights from the national inpatient sample
• The abnormalities of free fatty acid metabolism in patients with hypertrophic cardiomyopathy, a single-center retrospective observational study
• The impact of diabetes mellitus on cardiac function assessed by magnetic resonance imaging in patients with hypertrophic cardiomyopathy
• The Importance of the Effective Valsalva Maneuver during Echocardiography in Hypertrophic Cardiomyopathy
• The prognostic value of peak oxygen uptake in obstructive hypertrophic cardiomyopathy: a literature review to inform economic model development
• The promise of gene therapy in hypertrophic cardiomyopathy: emergence of human experience
• Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy
• Understanding the incidence of atrial fibrillation and stroke in hypertrophic cardiomyopathy patients: insights from Danish nationwide registries
• Understanding the incidence of atrial fibrillation and stroke in hypertrophic cardiomyopathy patients: insights from Danish nationwide registries
• Unveiling MiRNA-124 as a biomarker in hypertrophic cardiomyopathy: An innovative approach using machine learning and intelligent data analysis
• Utility and acceptability of remote 6-lead electrocardiographic monitoring in children with inherited cardiac conditions
• Ventricular late gadolinium enhancement by cardiac MRI as a predictor of atrial fibrillation in hypertrophic cardiomyopathy
• Vigorous Exercise in Patients with Hypertrophic Cardiomyopathy
• Viral myocarditis in combination with genetic cardiomyopathy as a cause of sudden death. An autopsy series